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Abstract
We developed a xenograft model of human Chronic Eosinophilic Leukemia (CEL) to study disease progression and
remission-induction under therapy with tyrosine kinase inhibitors using imatinib and nilotinib as examples. The FIP1L1/
PDGFRA+ human CEL cell lineEOL-1 was injected intravenously into scid mice, and MR imaging and FACS analysis of mouse
blood samples were performed to monitor disease development and the effects of imatinib and nilotinib. Organ infiltration
was analyzed in detail by immunohistochemistry after sacrifice. All animals developed CEL and within one week of therapy,
complete remissions were seen with both imatinib and nilotinib, resulting in reduced total tumor volumes by MR-imaging
and almost complete disappearance of EOL-1 cells in the peripheral blood and in tissues. The new model system is feasible
for the evaluation of new tyrosine kinase inhibitors and our data suggest that nilotinib may be a valuable additional
targeted drug active in patients with FIP1L1/PDGFRA+ CEL.
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Introduction
Chronic Eosinophilic Leukemia (CEL) is the most frequent
variant of myeloproliferative hypereosinophilic syndrome [1,2].
Neoplastic eosinophils in CEL display PDGFRA fusion genes in
most cases [3,4,5,6]. Most common are FIP1L1-PDGFRA (F/P)
fusions on 4q12, resulting in F/P
+ leukaemia [3,5,6]. The
FIP1L1-PDGFRA fusion protein is considered to cause both a
constantly upregulated cell proliferation and an increased
survival due to resistance to apoptosis of neoplastic eosinophils
[7,8].
For treatment of CEL, the tyrosine kinase inhibitor imatinib can
be used as first line therapy leading to rapid remission of
eosinophilia in most cases, and thus reducing organ infiltration
with the eosinophilic leukocytes [1,3,9].
EOL-1, a cell line established from the peripheral blood of a
patient suffering from CEL [8], has been used as an in vitro model
for the study of F/P
+ CEL [7]. In vivo EOL-1 cells form palpable
tumors after subcutaneous injection in severe combined immuno-
deficient (SCID) mice, and growth of these tumors can be
inhibited by tyrosine kinase inhibitors [10,11]. EOL-1 cells also
show hematologic engraftment after intravenous injection. The
latter, however, has only been demonstrated in irradiated NOD/
SCID mice so far [12].
As CEL is rare [1], it is rather difficult to recruit the number of
patients needed for studies to compare the effectiveness of different
(tyrosine kinase) inhibitors in treatment of the disease. Therefore, aim
of this study was the development of a human CEL xenograft in
immunodeficient mice without the need for irradiation in order to
study disease progression and remission under therapy with tyrosine
kinase inhibitors. For this purpose we used scid mice, which have
previously been more effective in treatment studies than NOD/SCID
mice [13]. We also show that nilotinib and imatinib are comparably
effective in this animal xenograft model. Imatinib and nilotinib are
inhibitors of the typrosine kinase activity of PDGFR, KIT and ABL/
BCR-ABL, but with a different selectivity profiles [14]. Both are
registered for the treatment of chronic myeloid leukemia.
Results
Nilotinib is comparably effective against EOL-1 cells in
vitro as imatinib
Imatinib and nilotinib both effectively induced apoptosis in the
human CEL cell line EOL-1 in vitro (Figure 1A). The apoptosis
inducing effects of both drugs were found to be dose-dependent
and of comparable magnitude (Figure 1B). Both drugs were also
found to inhibit proliferation of EOL-1 cells with almost identical
IC50 values (Figure 1C).
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All mice receiving injections of EOL-1 cells developed systemic
CEL. In the therapy group with a total of 11 animals in parts A
and B of the experiment four animals died before the end of the
experiment on day 35. Of these, one mouse died during anesthesia
after MR imaging and three died overnight after the start of
therapy on day 27. These mice all showed massive chloroma in the
MR images.
Figure 1. Induction of apoptosis and inhibition of proliferation of EOL-1 cells by imatinib and nilotinib in vitro. (A) EOL-1 cells were
cultured in medium supplemented with 1 nM imatinib (middle panel) or 1 nM nilotinib (right panel) for 48 hours. Fractions of active caspase 3
positive cells were quantified by flow cytometry. One typical experiment from three independent experiments is shown. (B) EOL-1 cells were cultured
in the absence (0) or presence of various concentrations of imatinib (left panel) or nilotinib (right panel). After incubation, cells were examined for the
percentage of apoptotic cells by light microscopy. Results represent the mean6S.D. from three independent experiments. (C) Dose-dependent
effects of imatinib (left panel) and nilotinib (right panel) on proliferation of EOL-1 cells. Cells were kept in control medium (0) or various
concentrations of imatinib or nilotinib for 48 hours. Thereafter,
3H-thymidine uptake was measured. Results show the percent 3H-thymidine uptake in
drug-exposed cells relative to control (100%) and represent the mean6S.D. from 3 independent experiments.
doi:10.1371/journal.pone.0030567.g001
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the experiment. Of these, one died overnight after the start of
treatment on day 28 and four had to be euthanized at some point
between days 28 and 35 due to reaching the endpoint criteria as
stated below. Upon necropsy, all of the latter animals showed
massive chloroma and EOL-1 infiltrations in various organs (see
below).
Analyzing imatinib versus placebo therapy
Flow cytometry of blood samples. Human HLA-DR was
chosen as a marker for detecting EOL-1 cells in blood and tissue
samples of imatinib or placebo treated mice, in order to avoid
cross reactions with murine cells. EOL-1 cells from cell culture
clearly displayed HLA-DR expression on their surface as analyzed
by flow cytometry (Figure 2A). EOL-1 cells could also be detected
in blood samples of the animals by staining with anti-HLA-DR.
Flow cytometric analysis of a blood sample from mouse pB4 on
day 35 is shown as an example (Figure 2B).
The percentage of EOL-1 of the non-erythrocyte cells in the
mouse blood was analyzed by flow cytometry. On day 28 after
injection, EOL-1 cells ranging from below 0.1 to 4% of the non-
erythrocytes could be detected in all animals. For part B of the
experiment, this percentage dropped to zero in the blood of the
imatinib-treated mice already on day 31 (4 days after therapy start)
and EOL-1 cells were still undetectable on day 35 (therapy day 8)
in the therapy group (Figure 2C). In the placebo treated group, the
percentage of EOL-1 cells increased from days 28 to 31 and even
more so to day 35, their percentage ranging from 2.2 to 81%
(Figure 2D). On day 35, two animals (pB1 and pB4) appeared
apathetic and in generally poor condition, which was due to a
manifest blast crisis (81% and 22% EOL-1 cells in the animals’
blood, Figure 2B, C); these animals had to be sacrificed according
to the animal welfare guidelines.
MRI. On day 27 (therapy day 0), massive tumor masses could
be detected in all mice by MR imaging. Under imatinib therapy
the total tumor volume (given in mm
3) decreased from a mean of
Figure 2. Flow Cytometry of blood samples. (A) EOL-1 cells grown in cell culture express HLA-DR: Histogram for anti-HLA-DR staining (filled
curve) versus isotype control (open curve). (B) EOL-1 cells could also be detected in mouse blood after xenotransplantation of EOL-1 cells. Staining of
EOL-1 cells with anti HLA-DR from the blood of mouse pB4 on day 35 after erythrolysis is shown. Human EOL-1 cells can clearly be distinguished from
murine leukocytes by size (forward scatter, FSC) and HLA-DR positivity (FL2-H). EOL-1 cells (upper right quadrant) constitute 22.2% of non-erythrocyte
cells in mouse blood. (C, D) Percentage of EOL-1 cells in mouse leukocytes (part B of the experiment) under imatinib treatment for the placebo group
(C) and the therapy group (D). Values are shown for day 28 (d28, black square), day 31 (d31, grey triangle) and day 35 (d35, black triangle). Missing
value for a mouse on a given day indicates that the mouse was no longer alive at this point of time.
doi:10.1371/journal.pone.0030567.g002
New Xenograft Model for Treatment of CEL
PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e30567428.96149.1 on day 27 (day 0 after start of therapy; range 1120.1
to 69.0 mm
3) to 156.0667.4 on day 30 (therapy day 3; range
461.0 to 10.3 mm
3) and further to 11.965.2 on day 34 (therapy
day 7; range 0.6 to 33.1 mm
3, Figure 3A).
In contrast, the tumor volumes drastically increased in the
placebo-treated group (again given in mm
3): From 153.6649.1 on
day 27 (range 45.1 to 343.9 mm3) to a mean of 446.8665.7 on
day 30 (range 252.6 to 599.1 mm
3) and to a mean of 12336172.4
on day 34 (range 536.1 to 1858.8 mm
3; Figure 3B). The
differences in mean total tumor volume between the therapy
and the placebo group were highly significant both on day 30
(therapy day 3) and 34 (therapy day 7; p,0.0001). Mean total
tumor volumes before and after 7 days of therapy for both groups
are given in Figure 3C. MR imaging on therapy days 0, 3 and 7 is
shown for one typical animal of each group in Figure 4.
Histology. On day 35 (therapy day 8) all animals were
sacrificed. Staining for human HLA-DR revealed EOL-1 cells in
sections of paraffin-embedded tissue samples. Chloromas
(granulocytic sarcomas) constituted large proportions of the total
tumor volume in most animals, however, in the imatinib-treated
mice most of the chloromas had gone into complete remission
after seven days of therapy. In chloromas from mice of the placebo
group, most of the cells were EOL-1 (HLA-DR positive, Figure 5A)
with only few mouse cells remaining, whereas almost no EOL-1
cells could be detected in sections of the few remains of chloromas
from the therapy group (Figure 5B). EOL-1 cells could be detected
in spleen and lung of the placebo-treated mice (Figure 5C, E), but
not in the imatinib-treated animals (Figure 5 D, F). Massive
infiltrations of EOL-1 cells were also found in liver (Figure 5G) of
all mice and in the spine of some (Figure 5H). The latter animals
developed paraplegia, which was reversible when the animals were
treated with imatinib.
Using the newly established xenograft model for the
evaluation of Nilotinib-treatment of CEL
For the evaluation of nilotinib for CEL-therapy, a total of six
mice per group were orally treated with either nilotinib or placebo,
respectively. Analysis of blood samples and MR imaging were
performed as described above. EOL-1 cells were not detectable in
mouse blood after 4 days of nilotinib treatment, whereas low
percentages of EOL-1 cells (0.1 to 1.2%) were detectable in the
placebo group. Total tumor volume as determined by MR images
was drastically reduced after 7 days of therapy in all nilotinib
treated mice. Development of total tumor volume for each animal
are shown Figure 6A and in Figure 6B for the placebo group.
Given in mm
3 the mean total tumor volumes for the nilotinib
treated group from days 27, 31 and 34 (therapy days 0, 4 and 7)
were 163.8650.4, 26.2610.7 and 3.461.4 and 63.93614.89,
108.3624.2 and 229.3647.6 for the placebo group, respectively.
Both on day 30 (therapy day 4) and 34 (therapy day 7) the
differences between the therapy and the placebo group were
highly significant (P,0.01, unpaired t-test, Figure 6C). Again some
animals showed signs of paraplegia, which were reversible under
nilotinib treatment.
Figure 3. Development of total chloroma volume as deter-
mined by MR imaging under imatinib treatment. (A) Total
chloroma volume in mm
3 for each animal from the therapy group on
days 27 (Therapy d0), 30 (Therapy d3) and 34 (Therapy d7). (B) Total
chloroma volume in mm
3 for each animal from the placebo group on
days 27 (Placebo d0), 30 (Placebo d3) and 34 (Placebo d7). (C) Total
chloroma volume in mm
3 for the therapy and placebo group before
(d0) and after (d7) imatinib treatment. n.s.: non-significant, P=0.1301;
***: highly significant, P,0.0001.
doi:10.1371/journal.pone.0030567.g003
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Clonal proliferation of eosinophilic leukocytes related to the Fip
1 alpha/BCR ABL mutation represents the most common form of
CEL, representing the myeloproliferative subtype of the hyper-
eosinophilic syndrome (HES) [6]. Epidemiologic data demonstrate
CEL to be a very rare disorder [1,3,5,6] and since testing for these
mutations in HES has not been performed frequently, incidence
rates are difficult to estimate. The low incidence and the absence
of screening for mutations both contribute to the fact that large
cohort studies to evaluate new drug therapies in HES are lacking.
Therefore the development of an animal model, closely resembling
human disease is essential to evaluate new therapeutic strategies in
vivo. To our knowledge so far only the NOD/SCID mouse model
demonstrated that immunodeficient mice are capable to host
EOL-1 cells in the murine circulation [12]. While this model
allowed insights into the proliferation and differentiation of EOL-1
cells in the mouse circulation, its practical value is clearly limited as
a lethal irradiation of the mice prior to the EOL-1 transfer had to
be performed. We therefore switched to SCID mice, which were
more suited to therapeutical intervention than NOD/SCID mice
in a human T-cell leukemia xenograft [13].
New in our model is the monitoring of the therapy in the mouse
blood using FACS analysis, which was not performed in previous
models using tyrosine kinase inhibitors or aurora inhibitors,
respectively [11,15].
Figure 4. MR imaging. MR images of one mouse each of the therapy (A, imatinib) and placebo group (B). Coronar (left panels) and sagittal (left
panels) T2 images of EOL-1 bearing scid mice on days 27 (d0 of treatment), 30 (d3 of treatment) and 34 (d7 of treatment). In the selected plane,
remission (therapy) or growth (placebo) of a large abdominal chloroma can be observed (arrows). Chloroma is in complete remission on day 34 under
imatinib treatment (A, d7).
doi:10.1371/journal.pone.0030567.g004
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e30567Figure 5. Histology. The presence of human EOL-1 cells was ascertained by labeling for human HLA-DR (seen in red) in tissue-sections. (A)
chloroma, placebo group; (B) former chloroma, therapy group with no viable EOL-1 cells detectable; (C) spleen, placebo; (D) spleen, therapy, with no
detectable EOL-1 cells; (E) lung, placebo; (E) lung, therapy, with no detectable EOL-1 cells; (F) liver, placebo, massive EOL-1 infiltrates; (G) spine,
placebo, with EOL-1 infiltrates in bone marrow.
doi:10.1371/journal.pone.0030567.g005
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imatinib and nilotinib against EOL-1 cells, which is in line with
data from literature for other cell lines [14]. In human patients,
treatment of CEL with imatinib is well established [7,9], however,
resistance of EOL cells to imatinib obviously does occur in an
increasing number of cases [16,17]. First case reports show an
efficacy of nilotinib in these cases [18]. In addition, the growth of
the EOL -1 cells/tumors at various sites could be monitored by
MR imaging for the first time and these findings could be verified
by histology.
In patients suffering from CEL, relevant clinical symptoms and
organ involvement vary, with splenomegaly being the only
common finding [19]. Although we could show the presence of
EOL-1 cells in the spleen of all mice from the placebo group
(Figure 4), we did not observe pronounced splenomegaly in the
animals. However, it has to be kept in mind that the role of the
murine spleen in hematopoesis differs from that in humans [20].
In FIP1L1/PDGFRA+ CEL, endomyocardial infiltrates of CEL
cells are often observed. However, we could not find EOL-1 cells
in sections of the animals’ hearts. EOL-1 cells were always
detectable in liver and spleen of the animals from the placebo
group and chloromas at various locations were always detected in
MR imaging of the mice. Chloromas (granulocytic sarcomas) have
been described in human CEL [21] and their incidence might be
underestimated in AML and generally in CML [22] as the
majority of chloromas is only diagnosed at autopsy [23]. We could
show that remission of EOL-1 leukemia was achieved by only a
one week treatment with intraperitoneal imatinib or with oral
nilotinib treatment in our xenograft model, respectively. With both
tyrosine kinase inhibitors, the mice showed no signs of disease
anymore (even paraplegia – if any – vanished after treatment).
Both drugs were comparably efficient in eliminating CEL cells
from the animals’ blood, organs and from the few remnants of
chloroma that could still be found at the necropsies. It is interesting
that both tyrosine kinase inhibitors showed a high efficacy in the
treatment of these solid nodules. The particular value of the new
model lies in the fact that the course of disease can be easily
monitored using both FACS and MR imaging.
Many studies have demonstrated tyrosine kinase inhibitors to
be highly effective in treatment of CEL (Valent review, das
polnische Paper). Long term remissions with molecular remis-
sions can be achieved in more than 90% [1,19]. However, after
successful induction of remission it still remains unclear how long
drug application has to be continued as a maintenance therapy
[1,19,24,25]. Despite the great benefit of tyrosine kinase
inhibitors, many studies report small numbers of patients who
develop resistance to tyrosine kinase inhibitor treatment which is
associated with a poor prognosis [17,19]. The mouse model
presented in this work will allow short term experiments to
investigate treatments with new (tyrosine kinase) inhibitors as well
as long term studies to understand the induction and mainte-
nance of remission and the development of resistance towards
tyrosine kinase inhibitors.
Figure 6. Development of total tumour volume as determined
by MR imaging under nilotinib treatment. (A) Total tumour
volume in mm
3 for each animal from the therapy group on days 27
(Therapy d0), 31 (Therapy d4) and 34 (Therapy d7). (B) Total tumour
volume in mm
3 for each animal from the placebo group on days 27
(Placebo d0), 31 (Placebo d4) and 34 (Placebo d7). (C) Total tumour
volume in mm
3 for the therapy and placebo group before (d0) and after
(d7) nilotinib-treatment. n.s.: non-significant, P=0.0869; ***: highly
significant, P=0.0008, unpaired t-test.
doi:10.1371/journal.pone.0030567.g006
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Tyrosine Kinase Inhibitors and other Reagents
The tyrosine kinase inhibitors imatinib (GleevecH) and nilotinib
(TasignaH) were kindly provided by Novartis (Basel, Switzerland).
RPMI 1640 medium and fetal calf serum (FCS) were purchased
from PAA laboratories (Pasching, Austria),
3H-thymidine from GE
Healthcare (Buckinghamshire, UK), and an antibody against
activate caspase 3 (C92-605) from Becton Dickinson Biosciences
(San Jose, CA, USA).
Cell Culture
EOL-1 cells (DSMZ, Braunschweig, Germany) were cultured in
RPMI 1640 medium, supplemented with 10% FCS, 2 mM L-
glutamine, 100 Uml
21 penicillin and 100 mgml
21 streptomycin
(all Invitrogen, Karlsruhe, Germany) at 37uC in a humidified
atmosphere of 5% CO2. To investigate drug effects, EOL- 1 cells
were incubated with control medium or in various concentrations
of imatinib (0.1–100 nM) or nilotinib (0.1–100 nM) at 37uC for
48 hours. Thereafter, the number of apoptotic cells and
3H-
thymidine uptake were measured. All experiments were performed
at least three times. In select experiments, expression of active
caspase 3 in EOL-1 cells was determined by flow cytometry after
drug exposure.
Animals
All animals used were pathogen-free Balb/c severe combined
immunodeficient scid mice aged 9–14 weeks with a weight of 25–
30 g at the beginning of the experiments. The animals were
housed in filter-top cages and provided food and water ad libitum.
Ethics Statement
The methodology for carrying out the animal experiments was
consistent with the UKCCR guidelines for the welfare of animals
in experimental neoplasia [26]. The experiment was supervised by
the institutional animal welfare officer, and approved by the local
licensing authority (Beho ¨rde fu ¨r Soziales, Familie, Gesundheit,
Verbraucherschutz; Amt fu ¨r Gesundheit und Verbraucherschutz;
Billstr. 80, D-20539 Hamburg, Germany) under the project
no. 41/08.
Establishing a mouse model for the treatment of human
CEL with Imatinib
The experiment (part A) was first carried out with 10 mice (5
animals for the therapy and the placebo group, respectively) and
repeated (part B) with 12 mice (6 animals each group). The mice
were designated with the letter t (for therapy group) or p (placebo
group) and a running number. In the following, each individual
animal will be referred to as for example ‘‘tB3’’ (therapy group,
experiment part B, mouse number 3). For injection, EOL-1 cells
were washed and resuspended in PBS at 2610
7 cells per ml. All
mice received an intravenous injection of 2610
6 EOL-1 cells (in
100 ml PBS) and were either treated with intraperitoneal injections
of imatinib (100 mg/kg body weight in 100 ml PBS) or PBS as
placebo control. The animals each received one injection per day
for 10 days.
27 days after the injection of the EOL-1 cells, the first MR
imaging was acquired and therapy started on the next day. MR
imaging was repeated on days 30 and 34. Additionally, blood was
taken on day 28 (experiment part A) and additionally on days 31
and 35 (part B only). All mice were sacrificed on day 35 after 7
days of treatment.
Nilotinib treatment
The animal experiment using nilotinib for EOL-treatment was
performed as described for imatinib above, except as follows.
Nilotinib was applied orally via gavage once per day for 7 days
(100 mg/kg body weight in 100 ml sterile water), placebo control
was sterile water.
MR imaging
The animals were anesthesized for approximately 45 minutes
by intraperitoneal injection of a weight-adapted dose (1 ml/g body-
weight) of a mixture of 1.2 ml Ketamin (Gra ¨ub AG., Bern, Manley
CH), 0.8 ml Rompun (Bayer AG, Leverkusen, Germany) und
8 ml physiological saline solution (Invitrogen). MRI was per-
formed on a clinical 3.0T MRI scanner (Intera, Philips Medical
Systems, Best, The Netherlands). The scanner was equipped with
a conventional body transmit coil and gradient system allowing a
maximal amplitude of 30 mT m
21 and a slew rate of
50 mT
21 s
21. For signal reception a dedicated four-element
mouse coil (Philips Research Laboratories, Hamburg, Germany)
with an inner diameter of 2.5 cm was used. The MR sequence
protocol consisted of a T1 weighted localizer sequence in three
orthogonal planes, an additional T2 weighted localizer in sagittal
orientation followed by a high-resolution fat saturated T1
weighted 2D turbo spin-echo sequence (TSE) in coronar
orientation, a fat saturated T2 weighted 2D TSE in coronar and
sagittal orientation. Image parameters of the whole body coronar
T1 TSE sequence were as follows: time of repetition (TR)/time of
echo (TE)/flip angle (FA)=1275 ms/33 ms/90u; field-of-view
(FOV)=100635 mm
2; matrix=4646464; slice thickness
(ST)=1 mm, number of slices (NS)=14; number of acquisitions
(NA)=3; spatial resolution=0,2260,2261 mm; acquisition
time=5 minutes 18 seconds. Image parameters of the fat
saturated whole body coronar and sagittal T2 TSE sequence
were as follows: TR/TE/FA=2361 ms/90 ms/90u; FOV=
100635 mm
2; matrix=4486448; ST=1 mm, NS=14; NA=3;
spatial resolution=0,2260,2261 mm; acquisition time=3 mi-
nutes 37 seconds. The tumor size was determined by measuring
the largest dimensions of the tumors height, length and width in
the coronar and sagittal plane.
Flow Cytometry
Each blood sample for FACS-analysis was prepared from
200 ml of fresh EDTA-blood as follows: Erythrolysis was
performed according to the manufacturer’s instructions using the
Mouse Erythrolysis Kit (R&D, Wiesbaden, Germany). Cells were
stained for 30 min on ice with phycoerythrin-labelled mouse anti-
human HLA-DR (BD, Heidelberg, Germany), diluted 1:50 in
100 ml FACS buffer (PBS, 1% BSA) or the corresponding isotype
control (Miltenyi, Bergisch-Gladbach, Germany). After washing,
cells were subjected to fluorescence assisted flow cytometry on a
FACSCalibur (BD). Files were analyzed using Win MDI 2.9
software.
Immunohistochemistry
Immunohistochemistry using sections of paraffin-imbedded
tumours was carried out as previously described [27]. Briefly,
after antigen retrieval (microwave, citrate buffer, ph=6), mouse
anti-HLA-DR alpha chain or corresponding isotype control was
used as first antibody, respectively, followed by incubation with
biotinylated rabbit anti-mouse (all Dako, Glostrup, Denmark) and
visualization using the streptavidin-alkaline-phosphatase based
Vectastain ABC kit (Vector, Burlingame, CA, USA). Slides were
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Mirax Viewer (Zeiss) software was used to take images.
Statistical analyses
Statistical Analysis was done using GraphPad Prism 5
(GraphPad, La Jolla, CA, USA). Tests used are given for each
value of P in the Results section.
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